Artículos de revistas
Beneficial Effect Of Crotamine In The Treatment Of Myasthenic Rats
Registro en:
Muscle And Nerve. , v. 47, n. 4, p. 591 - 593, 2013.
0148639X
10.1002/mus.23714
2-s2.0-84875602907
Autor
Hernandez-Oliveira e Silva S.
Rostelato-Ferreira S.
Rocha-e-Silva T.A.A.
Randazzo-Moura P.
Dal-Belo C.A.
Sanchez E.F.
Borja-Oliveira C.R.
Rodrigues-Simioni L.
Institución
Resumen
Introduction: Crotamine is a basic, low-molecular-weight peptide that, at low concentrations, improves neurotransmission in isolated neuromuscular preparations by modulating sodium channels. In this study, we compared the effects of crotamine and neostigmine on neuromuscular transmission in myasthenic rats. Methods: We used a conventional electromyographic technique in in-situ neuromuscular preparations and a 4-week treadmill program. Results: During the in-situ electromyographic recording, neostigmine (17 μg/kg) caused short-term facilitation, whereas crotamine induced progressive and sustained twitch-tension enhancement during 140 min of recording (50 ± 5%, P < 0.05). On the treadmill evaluation, rats showed significant improvement in exercise tolerance, characterized by a decrease in the number of fatigue episodes after 2 weeks of a single-dose treatment with crotamine. Conclusions: These results indicate that crotamine is more efficient than neostigmine for enhancing muscular performance in myasthenic rats, possibly by improving the safety factor of neuromuscular transmission. © 2012 Wiley Periodicals, Inc. 47 4 591 593 Dierdorf, S.F., Walton, S., Anesthesia for patients with rare and coexisting diseases (2006) Clinic anesthesia, p. 502. , Barash PG, Cullen BF, Soelting RK, editors., 5th ed. Philadelphia: Lippincott Williams and Wilkins Argov, Z., Management of myasthenic conditions: nonimmune issues (2009) Curr Opin Neurol, 22, pp. 493-497 Qian-Sheng, Y., Harold, W.H., Weiming, L., Debomoy, K.L., Arnold, B., Nigel, H., Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine (2010) Bioorg Med Chem, 18, pp. 4687-4693 Barrio, A., Vital Brazil, O., Neuromuscular action of the Crotalus terrificus terrificus poisons (1951) Acta Physiol Latinoam, 1, pp. 291-308 Gonçalves, J.M., Polson, A., The electrophoretic analysis of snake venoms (1947) Arch Biochem, 13, pp. 253-259 Gonçalves, J.M., Estudos sobre venenos de serpentes brasileiras. II-Crotalus terrificus crotaminicus, subespécie biológica (1956) Ann Acad Bras Ci{ring in equal to}nc, 28, pp. 365-367 Rádis-Baptista, G., Kerkis, I., Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties (2011) Curr Pharm Des, 17, pp. 4351-4361 Ownby, C.L., Structure, function and biophysical aspects of the myotoxins from snake venoms (1998) J Toxicol Toxin Rev, 17, pp. 213-238 Vital Brazil, O., Prado-Franceschi, J., Laure, C.J., Repetitive muscle responses induced by crotamine (1979) Toxicon, 17, pp. 61-69 Matavel, A.C.S., Ferreira-Alves, D.L., Beirão, P.S.L., Cruz, J.S., Tension generation and increase of voltage-activated sodium current by crotamine (1998) Eur J Pharmacol, 348, pp. 167-173 Vital Brazil, O., Fontana, M.D., Toxins as tools in the study of sodium channel distribution in the muscle fiber membrane (1993) Toxicon, 31, pp. 1085-1098 Chang, C.C., Tseng, K.H., Effect of crotamine, a toxin of South American rattlesnake venom, on the sodium channel of murine skeletal muscle (1978) Br J Pharmacol, 63, pp. 551-559 Camillo, M.A.P., Arruda Paes, P.C., Troncone, L.R.P., Rogero, J.R., Gyroxin fails to modify in vitro release of labeled dopamine and acetylcholine from rat and mouse striatal tissue (2001) Toxicon, 39, pp. 843-853 Kawanami, S., Mori, S., Experimental autoimmune myasthenia gravis induced by thymic acetylcholine receptor-like protein (1994) Fukuoka Igaku Zasshi, 85, pp. 120-127 Dal Belo, C.A., Leite, G.B., Fontana, M.D., Corrado, A.P., Zanandréa Baso, A.C., New evidence for a presynaptic action of prednisolone at neuromuscular junction (2002) Muscle Nerve, 26, pp. 37-43 Brown, G.L., The neuromuscular junction (1938) J Physiol, 92, p. 22 Priviero, F., De Nucci, G., Antunes, E., Zanesco, A., Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training (2004) Clin Exp Pharmacol Physiol, 31, pp. 741-743 Pourmand, R., Myasthenia gravis (1997) Dis Mon, 43, pp. 65-109 Tzartos, S.J., Barkas, T., Cung, M.T., Mamalaki, A., Marraud, M., Orlewski, F., Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor (1998) Immunol Rev, 163, pp. 89-120 Serra, A., Ruff, R., Kaminski, H., Leigh, J.R., Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles (2011) Ann NY Acad Sci, 1233, pp. 26-33 Pritchard, E.A.B., The use of "Prostigmin" in the treatment of myasthenia gravis (1935) Lancet, 1, pp. 432-434 Sieb, J.P., Myasthenia gravis: emerging new therapy options (2005) Curr Opin Pharmacol, 5, pp. 303-307 Mehndiratta, M.M., Pandey, S., Kuntzer, T., Acetylcholinesterase inhibitor treatment for myasthenia gravis (2011) Cochrane Database Syst Rev, 16, pp. CD006986 Mantegazza, R., Bonanno, S., Camera, G., Antozzi, C., Current and emerging therapies for the treatment of myasthenia gravis (2011) Neuropsychiatr Dis Treat, 7, pp. 151-160 Richman, D.P., Agius, M.A., Treatment of autoimmune myasthenia gravis (2003) Neurology, 61, pp. 1652-1661 Toyama, M.H., Marangoni, S., Novello, J.C., Leite, G.B., Prado-Franceschi, J., da Cruz-Höfling, M.A., Biophysical, histopathological and pharmacological characterization of crotamine isoforms F22 and F32 (2003) Toxicon, 41, pp. 493-500 Ponce-Soto, L.A., Martins-de-Souza, D., Novello, J.C., Marangoni, S., Structural and biological characterization of two crotamine isoforms IV-2 and IV-3 isolated from the Crotalus durissus cumanensis venom (2007) Protein J, 26, pp. 533-540 Ponce-Soto, L.A., Martins-de-Souza, D., Marangoni, S., Structural and pharmacological characterization of the crotamine isoforms III-4 (MYX4-CROCu) and III-7 (MYX7-CROCu) isolated from the Crotalus durissus cumanensis venom (2010) Toxicon, 55, pp. 1443-1452 Slater, C.R., Structural factors influencing the efficacy of neuromuscular transmission (2008) Ann NY Acad Sci, 1132, pp. 1-12